JOHNSON & JOHNSON — Director's Dealing 2020

Jun 26, 2020

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Fusion Pharmaceuticals Inc. (FUSN)
CIK: 0001805890
Period of Report: 2020-06-25

Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: Johnson & Johnson Innovation - JJDC, Inc. (10% Owner)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Class A Preferred Shares	$		Common Shares (1997876)		Indirect
Class B Preferred Shares	$		Common Shares (947640)		Indirect
Warrants to purchase Class B Preferred Shares	$8.10	2022-01-10	Common Shares (89118)		Indirect

Footnotes

F1: The Class A Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class A Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class A Preferred Shares have no expiration date.

F2: The securities reported as being indirectly beneficially owned by the designated Reporting Person are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of the designated Reporting Person.

F3: The Class B Preferred Shares are convertible into Common Shares on a one-for-5.339 basis. Upon the closing of the Issuer's initial public offering, the Class B Preferred Shares will convert into the number of Common Shares reported in Column 3, for no additional consideration. The Class B Preferred Shares have no expiration date.

F4: Upon the closing of the Issuer's initial public offering, the Warrants to purchase Class B Preferred Shares will become Warrants to purchase Common Shares at an exercise price of $8.10 per share.